Phase 2 Liver Cancer Trial, Recruiting NCT06467799 Sponsor: Sun Yat-sen University Condition: Liver Cancer
Back to Liver Cancer

Phase 2 Liver Cancer Trial, Recruiting

NCT06467799
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been newly diagnosed with liver cancer (hepatocellular carcinoma) and have not yet received any treatment for it
  • Your tumor is considered larger than usual guidelines allow for standard treatment — either one tumor larger than 5 cm, or 2–3 tumors where the largest is bigger than 3 cm — but your cancer may still be removable by surgery
  • Your cancer has not spread to nearby blood vessels, lymph nodes, or other parts of the body
  • Your liver is large enough that enough healthy liver tissue would remain after surgery (confirm with trial site)
  • You are in good overall physical health, able to carry out normal daily activities with no significant limitations
  • Your liver is functioning well, based on a standard medical scoring system called Child-Pugh class A (confirm with trial site)
  • Your expected survival is more than 6 months
  • Your blood counts, liver function, and kidney function all meet specific healthy levels as measured by blood tests (confirm with trial site)
  • You are willing and able to sign a consent form, take medications as required, and attend follow-up appointments as set out in the study

Who may not be able to join:

  • You have serious problems with your heart, lungs, kidneys, or other major organs, or you have an active infection (other than hepatitis) or other serious health conditions that would make treatment unsafe
  • You have a medical reason why surgery or immunotherapy (treatments that work with your immune system) would not be suitable for you
  • You have had another type of cancer in the past
  • You have a disease affecting your immune system, or you need to take steroid medications long-term for any condition
  • You are known or believed to be allergic to the study drug or any other medicines used in this trial
  • You have previously had an organ transplant
  • You are currently pregnant or breastfeeding
  • There are other factors that the trial team believes could affect your participation or the results of the study (confirm with trial site)
  • You are unwilling to attend follow-up appointments as required or unwilling to sign the consent form

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yaojun Zhang, MD, PHD, Sun Yat-Sen University Cancer Center

Phone: +8613719433968

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 September 2024
Est. completion
1 September 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

recurrence free survival, RFS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov